Thermo Fisher Scientific Announces Preview of Fully Integrated Clinical Analyzer at AACC 2017
Complete the form below to unlock access to ALL audio articles.
Following a successful introduction to the European market at EuroMedLab in Athens, Greece last month, Thermo Fisher Scientific announces the U.S. preview of the Thermo Scientific Cascadion SM Clinical Analyzer bringing together the ease of use of clinical analyzers with the selectivity and sensitivity of liquid chromatography-tandem mass spectrometry (LC-MS/MS).
The fully automated Cascadion analyzer is designed for use by non-experts in a variety of settings, including hospital laboratories, to provide results for a range of frequently ordered tests. The Cascadion analyzer is available for demonstrations in booth #4039 during the 2017 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo, being held July 31 – August 3 at the San Diego Convention Center. The company will seek CE mark followed by FDA approval.
"This is a marvelous development, and it is really quite outstanding. It will fulfill the needs of many laboratories," said Professor Brian Keevil, consultant clinical scientist and head of the Clinical Biochemistry Department, University Hospital of South Manchester NHS Foundation Trust, UK, after viewing a demonstration during EuroMedLab 2017.
The Cascadion system was designed and built using Thermo Fisher products and technologies combined with its industry-leading expertise in mass spectrometry. Featuring turnkey operation, the Cascadion analyzer is designed to be used by laboratory staff with no specialized training.
James Nichols, PhD, medical director, Chemistry and Point of Care Testing, Vanderbilt University Medical Center, added, "For much of what we do in terms of chromatography and mass spectrometry, we need very highly skilled and experienced medical technologists. The Cascadion analyzer is relatively maintenance-free and because it includes specially designed reagent kits, there is not a lot of interaction required with the technology."
After previewing the Cascadion analyzer, Michael Vogeser, senior physician and professor of laboratory medicine, University Hospital of Munich, stated "About 70% of all physician's decisions are based on laboratory tests so the impact on laboratory testing is huge and this completely new technological approach is of enormous value to mankind."
